Ancrod enhances the thrombolytic effect of streptokinase and urokinase.
Since thrombi continue to incorporate fibrin during lysis we tested the effect of pretreatment with ancrod, a defibrinating agent from Malaysian pit viper venom, on thrombolysis with urokinase and streptokinase. Thrombi were induced by copper-coils in the carotid arteries of the dogs, weighed after 1 hour and inserted into the femoral arteries of the same animals. They were then exposed for 15 min to iv boluses of streptokinase 10,000 U/kg, urokinase 10,000 U/kg and urokinase 25,000 U/kg with or without pretreatment with ancrod. Ancrod depleted fibrinogen within 5 min and enhanced the lytic effect of streptokinase from 25 +/- 8% to 59 +/- 13% (p less than .05), urokinase 10,000 U/kg from 16 +/- 11% to 66 +/- 18% (p less than .01) and urokinase 25,000 U/kg from 27 +/- 17% to 85 +/- 8% (p less than .001) of the initial thrombus weight. Ancrod itself did not activate plasminogen to plasmin. We conclude that ancrod enhances thrombolysis probably by depleting fibrinogen and preventing new fibrin incorporation into the thrombus during lysis.
Cercek
B
B
Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA.
Lew
A S
AS
Hod
H
H
Yano
J
J
Lewis
B
B
Reddy
K N
KN
Ganz
W
W
D000721:Ancrod / Q000494:pharmacology*; D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects; D004285:Dogs; D004357:Drug Synergism; D005340:Fibrinogen / Q000037:antagonists & inhibitors / Q000097:blood; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D013300:Streptokinase / Q000494:pharmacology*; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology*
D005343:Fibrinolytic Agents; D005340:Fibrinogen; D013300:Streptokinase; D000721:Ancrod; D014568:Urokinase-Type Plasminogen Activator